Why the study?
Redo sternotomy for prosthetic mechanical valve thrombosis can carry prohibitively high risk, and optimal dosing and patient selection for thrombolytic therapy remain incompletely characterized for right-side mechanical valves.
Thrombolytic therapy with tissue plasminogen activator may serve as an effective noninvasive alternative to high-risk redo sternotomy for right-sided mechanical valve thrombosis.
Supports thrombolysis consideration in right-sided mechanical valve thrombosis; hypothesis-generating case report requiring prospective validation.
Prosthetic mechanical valve thrombosis has traditionally been managed with urgent surgical intervention. However, the risk of redo sternotomy can be prohibitively high in some patients. Thrombolytic therapy as a noninvasive treatment of mechanical valve thrombosis is a well-recognized alternative, but optimal dosing and patient selection remain incompletely characterized for right-side mechanical valves.
No takes yet. Share an insight, caveat, or question.
Haraf et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: